Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection
BACKGROUND: Due to the limitations of existing treatment options for Clostridium difficile infection (CDI), new therapies are needed.
Saved in:
Main Authors: | George G Zhanel, Andrew J Walkty, James A Karlowsky |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2015/934594 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
by: Anke van Engen, et al.
Published: (2015-05-01) -
Clinical and Economic Consequences of Vancomycin and Fidaxomicin for the Treatment of Clostridium difficile Infection in Canada
by: Monika Wagner, et al.
Published: (2014-01-01) -
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
by: Thomas Louie, et al.
Published: (2015-12-01) -
Yersinia Infection with Clostridium Difficile Colitis
by: M.J. Fishman, et al.
Published: (1989-01-01) -
Caring at the transition: success and financial barriers of fidaxomicin discharge prescriptions for inpatients with Clostridioides difficile infection
by: Ellen Earle, et al.
Published: (2025-01-01)